top of page
HIMALAYA trial outcomes, survival data, dosing regimen, and immunotherapy combination strategies

This lesson is only available on the BackTable mobile app.

BackTable Tumor Board

Lesson 9  •  22 Jan 2025

HIMALAYA trial outcomes, survival data, dosing regimen, and immunotherapy combination strategies

with Dr. Lingling Du, Dr. Jonathan Mizrahi, Dr. Adam Burgoyne, Dr. Zach Berman, Dr. Tyler Sandow

Course overview

This course explores a multidisciplinary approach to HCC care, covering patient flow in combined clinics, the role of combination therapies and clinical trials for advanced HCC, and strategies for managing complex cases and BCLC B patients in the "grey" zone. The course is supported by an educational grant from AstraZeneca, with additional support from Boston Scientific.

To earn CME/CE credits for this course, it must be completed on the BackTable+ website.

2 CME/CE credits, 2 hours, 20 lessons

Lessons

Patient Flow: Navigating the Patient Experience with a Multidisciplinary Clinic



Lesson 1

Introduction



Lesson 2

Establishing diagnosis and treatment pathways for HCC within a multidisciplinary team



Lesson 3

Integrating follow-up HCC care, patient engagement, and clinical collaboration



Lesson 4

Interdisciplinary teamwork in transplant evaluation and the critical role of IR clinics in coordinated care



Lesson 5

Optimizing HCC referral pathways in community settings



Lesson 6

Handling patient HCC treatment schedules and integrating transplant considerations



Lesson 7

The importance of patient navigators, and strategies for improving HCC care





Combination Therapy & Clinical Trails for Advanced HCC: What They Really Mean



Lesson 8

Immunotherapy mechanism of action and key clinical trials in advanced HCC



Lesson 9

HIMALAYA trial outcomes, survival data, dosing regimen, and immunotherapy combination strategies



Lesson 10

CheckMate 9DW trial results, survival curves, dosing, and etiology impacts for HCC immunotherapy treatments



Lesson 11

Advanced HCC trial populations, real-world liver function, and criteria for administering immunotherapy



Lesson 12

Immunotherapy issues, including hepatitis and pneumonitis, and the effectiveness of combination treatments in HCC care



Lesson 13

Combination locoregional therapies and systemic therapies and their impacts on patient outcomes



Lesson 14

Optimal timing and dosing strategies for combining Y90 radioembolization with immunotherapy in cancer treatment





The "Grey" Zone, BCLC B & Complex HCC Patients



Lesson 15

BCLC guidelines, focusing on performance status, liver function, and treatment options for HCC patients



Lesson 16

ALBI score, LFT-s, and treatment strategies for HCC



Lesson 17

Response intervals and therapeutic approaches for systemic and liver-directed cancer treatments in complex cases



Lesson 18

When to use systemic vs liver-directed therapy, performance status, multidisciplinary care, and patient autonomy



Lesson 19

The challenges of differing medical opinions in HCC cancer



Lesson 20

Impacts of combinatorial approaches and treatment sequence in HCC care

Access the full course for free on the BackTable mobile app.

The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.

bottom of page